Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive–Compulsive and Impulsive Features in Adults with Binge Eating Disorder. (1st December 2015)

• Record Type: Journal Article
• Authors: McElroy, Susan L.; Mitchell, James E.; Wilfley, Denise; Gasior, Maria; Ferreira‐Cornwell, M. Celeste; McKay, Michael; Wang, Jiannong; Whitaker, Timothy; Hudson, James I.
• Is Part Of: European eating disorders review. Volume 24:Number 3(2016:May)
• Page Start: 223
• Page End: 231
• Publication Date: 2015-12-01
• Subjects: binge eating disorder -- impulsivity -- lisdexamfetamine dimesylate -- obsessive–compulsive; Eating disorders -- Periodicals; 616.8526
• DOI: 10.1002/erv.2418
• Languages: English
• ISSNs: 1072-4133

Abstract

Abstract: In a published 11‐week, placebo‐controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced binge eating days (primary endpoint) in adults with binge eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three‐Factor Eating Questionnaire [TFEQ]; Yale–Brown Obsessive Compulsive Scale modified for Binge Eating [Y‐BOCS‐BE]; and the Barratt Impulsiveness Scale, version 11 [BIS‐11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES ( p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y‐BOCS‐BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS‐11 total score at 70 mg/d LDX ( p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p <0.05). These findings indicate that LDX decreased global binge eating severity and obsessive–compulsive and impulsive features of BED in addition to binge eating days. Copyright © 2015 John Wiley & Sons, Ltd and Eating Disorders Association.